11 assistance programs for Remicade patients · 2 open today
Manufacturer savings, charitable foundations, and patient assistance programs.
Select the patient's insurance and diagnosis to see which programs may apply.
Current status · Award amounts · Eligibility · Direct application links · verified September 10, 2026
Remicade · Crohn's disease (adult) · Commercial insurance
Eligible patients may pay $5 per infusion
Example · Remicade · 400 mg · 40 units · commercial plan · deductible met · 20% coinsurance · allowed amounts at the Medicare reference rate
| Without assistance | With J&J withMe | |
|---|---|---|
| Drug responsibility | $251.83 | $5.00 |
| Administration (96413 + 96415) | $32.33 | $32.33 |
| Patient owes | $284.16 | $37.33 |
Estimated patient savings: $246.83
CareCost calculates the drug and administration lines using the patient’s payer rate and benefits; this example uses the Medicare rate as a reference.
Checked, and not available for this drug today
Free Johnson & Johnson Patient Assistance Program for eligible patients
Change the diagnosis to see only the programs that apply to your patient.
Remicade shares this HCPCS family with three biosimilars — Inflectra, Renflexis and Avsola. The J&J withMe programs above apply to Remicade only. If the payer requires one of the other three products instead, use that manufacturer’s program below.
A biller who lands here after being told the payer mandates Inflectra, Renflexis or Avsola instead of Remicade needs the program for that product, not the one above. Each biosimilar’s All three work the same way — eligible commercially insured patients pay $0, or $5 on a first fill, and the help covers the drug copay only, not the infusion administration or the office visit. What differs is the annual cap.
Pfizer enCompass Co-Pay Assistance Program (Inflectra)
Organon Co-pay Assistance Program (Renflexis)
Amgen SupportPlus Co-Pay Program (Avsola)
These three programs are tracked separately from the Remicade programs above and were last verified April 8, 2026. None of them cover infusion administration or office-visit fees, and none apply to patients on Medicare, Medicaid, TRICARE or VA insurance.
| Task | ✓ |
|---|---|
| Find programs for the diagnosis | ✓ |
| See whether each program is open | ✓ |
| See maximum award | ✓ |
| Review key eligibility requirements | ✓ |
| Open the official application | ✓ |
| Calculate cost before assistance | ✓ |
| Apply the program benefit | ✓ |
| Calculate what the patient still owes | ✓ |
Commercial insurance — Eligible commercially insured patients may qualify for the J&J withMe Savings Program. Eligible patients may pay $5 per infusion for the medication, subject to current program terms and limits. View current program ↑
Medicare — Manufacturer copay savings cannot be used when government insurance is paying for Remicade; the federal Anti-Kickback Statute is why, per HHS OIG guidance on copayment coupons. Diagnosis-specific charitable foundations may provide help with copays, coinsurance, deductibles or other qualifying costs when funding is available. View current Medicare funds ↑
Why fund status matters — Foundation funds can change between: OPEN Accepting applications now · WAITLIST Not enrolling immediately · CLOSED Not accepting new applications. Every CareCost program card shows the status and the date it was verified.
Why diagnosis matters — Foundation assistance is generally organized around the patient's diagnosis rather than the drug alone. Two patients receiving Remicade may therefore have completely different assistance options.
Yes. The current manufacturer savings program is the J&J withMe Savings Program. Eligible commercially insured patients may pay $5 per infusion for eligible medication costs, subject to program terms. Apply on J&J withMe ↗ Calculate cost with the program →
No. Patients using Medicare or other government-funded insurance to pay for Remicade are not eligible for the manufacturer's copay savings program. Independent charitable funds may still be available. Check current Medicare funds ↑
The applicable IBD funds above show their current verified status. Fund availability changes as foundations receive and exhaust funding. Check today's status ↑
Data current: programs verified Sep 10, 2026
J&J withMe Savings Program · Johnson & Johnson Patient Assistance Program · TotalAssist (Patient Advocate Foundation, merged with PAN Foundation in 2026) · HealthWell Foundation · Pfizer enCompass Co-Pay Assistance Program (Inflectra) · Organon Co-pay Assistance Program (Renflexis) · Amgen SupportPlus Co-Pay Program (Avsola). Every program links directly to its official source or application page.
Last program check: .
Reviewed September 10, 2026 by Erin Rose, CareCost Estimate founder. Methodology →
CareCost